Judging from the overall performance in the first half of the year, JD Health achieved steady growth. Its profitability mainly came from the increase in market share of core advantage categories, enhanced user stickiness, and the increase in gross profit margin brought about by improved supply chain efficiency.
In the first half of 2024, JD Health fully utilized the whatsapp number in australia advantages of the pharmaceutical and health supply chain, and the pharmaceutical retail business grew strongly, and JD's brand awareness of buying medicines was further strengthened. During this period, JD Health launched online a number of new and special medicines, including Xingqi Eye Medicine's 0.01% atropine sulfate eye drops Meiopin, Sanofi's new drug Zhilida, and Jinsai's new drug Meishiya.
The value effect of "the first station for the first launch of new and special medicines on the entire network" was significant; at the same time, JD Health's offline DTP pharmacy also sold the first domestic out-of-hospital channel Alzheimer's disease targeted drug Leyibao®, which fully demonstrated the advantages of JD Health's omni-channel supply chain in the universal accessibility of medicines.
The vigorous development of third-party cooperative merchants has also greatly enriched JD Health's product categories and service supply. As of June 30, the number of JD Health's third-party merchants reached 80,000, a year-on-year increase of more than 100%. In the process of cooperation, JD Health helps platform merchants improve their operating efficiency and digital marketing capabilities, deeply explore and accurately match user needs, and achieve common development with merchants.